Transplant Medicine

U.S. FDA OKs phase 2b kidney transplant trial for immunosuppressive drug

Published in Blood Weekly, June 16th, 2005

Isotechnika Inc. announced that the company has received permission from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2b kidney transplant trial for its lead immunosuppressive drug, ISA247.

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada.

The company was founded in 1993 by Dr. Robert Foster.

Drawing upon its expertise in medicinal chemistry and immunology, the company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments.

This article was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry